






[Skip to main content](#)

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

nature
nanotechnology

- [View all journals](#)
- [Search](#) 
- [Login](#) 

- [Explore content](#) 
- [About the journal](#) 
- [Publish with us](#) 

Subscribe

- [Sign up for alerts](#) 
- [RSS feed](#)

[nature](#) >

[nature nanotechnology](#) >

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

[Manage Settings](#)

[Accept All Cookies](#)

- Tanmoy Saha^{1,2},
- Chinmayee Dash ORCID: orcid.org/0000-0002-2677-603X^{1,2},
- Ruparoshni Jayabalan^{1,2},
- Sachin Khiste^{1,2},
- Arpita Kulkarni ORCID: orcid.org/0000-0003-0775-8044¹,
- Kiran Kurmi³,
- Jayanta Mondal^{1,2},
- Pradip K. Majumder⁴,
- Aditya Bardia ORCID: orcid.org/0000-0003-4885-1157⁵,
- [...]
- Hae Lin Jang¹ &
- Shiladitya Sengupta¹ ORCID: orcid.org/0000-0002-8065-5052^{1,2,6}
- -Show fewer authors

Nature Nanotechnology (2021)

- 2822 Accesses
- 1 Citations
- 440 Altmetric
- [Metrics details](#)

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

nanotube-mediated transfer of mitochondria from immune cells to cancer cells metabolically empowers the cancer cells and depletes the immune cells. Inhibiting the nanotube assembly machinery significantly reduced mitochondrial transfer and prevented the depletion of immune cells. Combining a farnesyltransferase and geranylgeranyltransferase 1 inhibitor, namely, L-778123, which partially inhibited nanotube formation and mitochondrial transfer, with a programmed cell death protein 1 immune checkpoint inhibitor improved the antitumour outcomes in an aggressive immunocompetent breast cancer model. Nanotube-mediated mitochondrial hijacking can emerge as a novel target for developing next-generation immunotherapy agents for cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from **\$8.99**

[Rent or Buy](#)

All prices are NET prices.

Subscribe to Journal

Get full journal access for 1 year

99,00 €

only 8,25 € per issue

[Subscribe](#)

Tax calculation will be finalised during checkout.

Additional access options:

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

[Manage Settings](#)

[Accept All Cookies](#)

Fig. 2: Nanotubes mediate organelle transfer between immune cells and cancer cells.

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

Fig. 4: Mechanism underlying nanotube formation and mitochondrial transfer.

Fig. 5: Targeting nanotube-mediated mitochondrial biotransfer augments antitumour immune

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

Data availability

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

References

1. Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. *Cell* **170**, 1120–1133.e17 (2017).
2. Sharma P. & Allison J. P. Dissecting the mechanisms of immune checkpoint therapy. *Nat. Rev.*

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. *Cancer Discov.* **8**, 1069–1086 (2018).

6. Tseng, D. et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. *Proc. Natl Acad. Sci. USA* **110**, 11103–11108 (2013).

7. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. *Science* **348**, 56–61 (2015).

8. Önfelt, B., Nedvetzki, S., Yanagi, K. & Davis, D. M. Cutting edge: membrane nanotubes connect immune cells. *J. Immunol.* **173**, 1511–1513 (2004).

9. Sowinski, S. et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. *Nat. Cell Biol.* **10**, 211–219 (2008).

10. Gousset, K. et al. Prions hijack tunnelling nanotubes for intercellular spread. *Nat. Cell Biol.* **11**, 328–336 (2009).

11. Osswald, M. et al. Brain tumour cells interconnect to a functional and resistant network. *Nature* **528**, 93–98 (2015).

12. Connor, Y. et al. Physical nanoscale conduit-mediated communication between tumour cells and the endothelium modulates endothelial phenotype. *Nat. Commun.* **6**, 8671 (2015).

13. Rustom, A., Saffrich, P., Markovic, I., Walther, P. & Gerdes, H. H. Nanotubular highways for

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

16. **16.** Lu, J. et al. Tunneling nanotubes promote intercellular mitochondria transfer followed by increased invasiveness in bladder cancer cells. *Oncotarget* **8**, 15539–15552 (2017).
17. Sena, L. A. et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. *Immunity* **38**, 225–236 (2013).
18. Kumar, A. et al. Enhanced oxidative phosphorylation in NKT cells is essential for their survival and function. *Proc. Natl Acad. Sci. USA* **116**, 7439–7448 (2019).
19. Vyas, S., Zaganjor, E. & Haigis, M. C. Mitochondria and cancer. *Cell* **166**, 555–566 (2016).
20. Goldman, A. et al. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. *Sci. Signal.* **12**, eaas8779 (2019).
21. Clutton, G., Mollan, K., Hudgens, M. & Goonetilleke, N. A reproducible, objective method using MitoTracker® fluorescent dyes to assess mitochondrial mass in T cells by flow cytometry. *Cytometry* **95**, 450–456 (2019).
22. Pham, A. H., McCaffery, J. M. & Chan, D. C. Mouse lines with photo-activatable mitochondria to study mitochondrial dynamics. *Genesis* **50**, 833–843 (2012).
23. Pelletier, M., Billingham, L. K., Ramaswamy, M. & Siegel, R. M. in *Methods Enzymol*, Vol. 542 (eds Galluzzi, L. & Kroemer, G.) 125–149 (Academic Press, 2014).
24. Kaplan, J. et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

27. **27.** Moskalenko, S. et al. The exocyst is a Ral effector complex. *Nat. Cell Biol.* **4**, 66–72 (2002).
- 28.** Hanna, S. J. et al. The role of Rho-GTPases and actin polymerization during macrophage tunneling nanotube biogenesis. *Sci. Rep.* **7**, 8547 (2017).
- 29.** Guo, W., Tamanoi, F. & Novick, P. Spatial regulation of the exocyst complex by Rho1 GTPase. *Nat. Cell Biol.* **3**, 353–360 (2001).
- 30.** Fransson, Å., Ruusala, A. & Aspenström, P. The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial trafficking. *Biochem. Biophys. Res. Commun.* **344**, 500–510 (2006).
- 31.** Glater, E. E., Megeath, L. J., Stowers, R. S. & Schwarz, T. L. Axonal transport of mitochondria requires milton to recruit kinesin heavy chain and is light chain independent. *J. Cell Biol.* **173**, 545–557 (2006).
- 32.** Arkwright, P. D. et al. Fas stimulation of T lymphocytes promotes rapid intercellular exchange of death signals via membrane nanotubes. *Cell Res.* **20**, 72–88.
- 33.** Bustelo, X. R., Sauzeau, V. & Berenjano, I. M. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. *Bioessays* **29**, 356–370 (2007).
- 34.** Majumder, B. et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. *Nat. Commun.* **6**, 6169 (2015).

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

of the National Nanotechnology Coordinated Infrastructure Network (NNCI), supported by the National Science Foundation. We thank M. Haigis and A. Goldman for help with the PhAM mouse studies. K.K. is a Gilead Sciences Fellow of the Life Sciences Research Foundation.

Author information

Affiliations

1. Center for Engineered Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Tanmoy Saha, Chinmayee Dash, Rugaroshni Jayabalan, Sachin Khiste, Arpita Kulkarni, Jayanta Mondal, Hae Lin Jang & Shiladitya Sengupta

2. Harvard–MIT Program in Health Sciences and Technology, Cambridge, MA, USA

Tanmoy Saha, Chinmayee Dash, Rugaroshni Jayabalan, Sachin Khiste, Jayanta Mondal & Shiladitya Sengupta

3. Department of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA

Kiran Kurmi

4. Mitra Biotech, Woburn, MA, USA

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

Contributions

T.S. conceived the project, designed and executed the experiments, analysed the data, prepared the figures, and contributed to writing the manuscript. C.D. and R.J. helped in designing and executing the in vitro experiments. S.K. and J.M. helped in designing and executing the in vivo studies and analysed results. A.K. performed the genotyping experiment, analysed results and helped write the manuscript. K.K. helped with the Dendra2 mice and Seahorse studies. P.K.M. and A.B. helped with human tumour explant studies and contributed to the manuscript writing. H.L.J. and S.S. conceptualized and supervised the project, and guided the experimental design, data analysis and manuscript writing.

Corresponding authors

Correspondence to [Hae Lin Jang](#) or [Shiladitya Sengupta](#).

Ethics declarations

Competing interests

S.S. is a co-founder and owns equity in Vyome Therapeutics, Akamara Therapeutics and Invictus Oncology, and receives fees from Famygen and Advamedica. H.L.J. is a founder and owns equity in Curer. A.B. is involved in the following consulting/advisory boards: Pfizer, Novartis, Genentech, Merck, Redix Health, Immunomedics, Teikyo, Sanofi, Daiichi Pharm/AstraZeneca, Duma, Biotherapeutics

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

Peer review information *Nature Nanotechnology* thanks the anonymous reviewers for their contribution to the peer review of this work.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Supplementary Figs. 1–29 and Table 1.

Reporting Summary

Rights and permissions

[Reprints and Permissions](#)

About this article

Cite this article

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies

Subjects [Biotechnology](#) • [Nanoscience and technology](#)

Further reading

- **Cancer cells hijack T-cell mitochondria**

Jeremy G. Baldwin & Luca Gattinoni

Nature Nanotechnology (2021)

Nature Nanotechnology (*Nat. Nanotechnol.*) ISSN 1748-3395 (online) ISSN 1748-3387 (print)

© 2021 Springer Nature Limited

Your privacy

We use cookies to make sure that our website works properly, as well as some "optional" cookies to personalise content and advertising, provide social media features and analyse how people use our site. By accepting some or all optional cookies you give consent to the processing of your personal data, including transfer to third parties, some in countries outside of the European Economic Area that do not offer the same data protection standards as the country where you live. You can decide which optional cookies to accept by clicking on "Manage Settings", where you can also find more information about how your personal data is processed. [View our privacy policy](#)

Manage Settings

Accept All Cookies